GKWIM
ATRA icon

Gerber Kawasaki Wealth & Investment Management’s Atara Biotherapeutics ATRA Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8
Closed -$3K – 343
2021
Q3 		$3K Buy
+8
New +$2.87K ﹤0.01% 816

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's ATRA Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Atara Biotherapeutics (ATRA) in Q4 2021, closing a stake of 8 shares — an estimated $3K sold.

Gerber Kawasaki Wealth & Investment Management first reported a position in ATRA in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 139 funds tracked by Wall St. Rank hold ATRA as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Atara Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 8 Atara Biotherapeutics shares in Q4 2021, an estimated $3K.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Atara Biotherapeutics in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's Atara Biotherapeutics position peaked at $3K in Q3 2021.
  • 139 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.